For over a decade, oral PrEP was the only option. Take it daily, stay protected. It worked, but only for people who could take it daily.
Now you have choices. Daily pills remain. Cabotegravir (Apretude), injected every two months. Lenacapavir (Yeztugo), injected every six months. All three FDA-approved. All three CDC-recommended. All three indistinguishable in efficacy when taken as prescribed.
The question is no longer “Do you want PrEP?” It is “Which PrEP fits the life you actually live?”
At Reza Health, we help you answer that.
Oral PrEP: The Known Quantity
Daily oral PrEP, specifically tenofovir disoproxil fumarate/emtricitabine (Truvada and its generics), has been available since 2012. It reduces sexual HIV transmission risk by up to 99% when taken consistently.
Who it fits best:
Oral PrEP is often the best fit for patients who value autonomy and prefer managing their HIV prevention independently without frequent scheduled visits. It works well for those who already maintain consistent daily medication routines and do not find pill-taking burdensome.
It is also the most affordable option for many individuals, as generic oral PrEP is inexpensive and, under the Affordable Care Act, most insurers are required to cover it without cost-sharing, making it both accessible and financially predictable.
The limitation:
It requires adherence. Not most days. Every day. Clinical trials measure efficacy under perfect use; real-world effectiveness drops when pills are missed. Patients who struggle with daily medication, due to housing instability, substance use, privacy concerns, or simply the cognitive load of taking a pill for a condition they do not feel, have historically been left behind by oral-only prevention.
Cabotegravir (Apretude): The Two-Month Window
Approved in 2021, cabotegravir long-acting injectable was the first alternative to daily pills. It requires an intramuscular injection in the gluteal region every eight weeks, following two initiation doses one month apart.
Efficacy:
In HPTN 083 (cisgender men and transgender women who have sex with men), cabotegravir demonstrated 69% fewer HIV infections compared to daily oral FTC/TDF. In HPTN 084 (cisgender women), the risk reduction reached 90%. The difference was not pharmacological superiority; it was adherence. Patients showed up for their injections. They did not always take their pills.
Who it fits best:
Injectable PrEP is well suited for patients who value privacy and prefer not to have pill bottles or medication shipments arriving at home. It appeals to those who would rather attend a small number of scheduled clinic visits each year instead of making daily medication decisions.
It is also an excellent option for individuals who are comfortable with intramuscular injections and appreciate the simplicity of a long-acting prevention approach.
Lenacapavir (Yeztugo): The Six-Month Horizon
June 2025 marked a new category. Lenacapavir, administered as a subcutaneous injection every six months, received FDA approval based on PURPOSE-1 and PURPOSE-2 trials demonstrating 100% efficacy among females and 96% efficacy among a primarily male trial population compared to background HIV incidence.
What the data showed:
In PURPOSE-2, 99% of participants in the lenacapavir group remained HIV-negative. Among 2,179 participants receiving lenacapavir, two acquired HIV. Among 1,086 participants receiving daily Truvada, nine acquired HIV. Again, the mechanism is adherence. Twice-yearly injection removes 363 days of potential non-adherence per year.
Who it fits best:
Lenacapavir is a strong option for patients who travel frequently, have unpredictable schedules, or find it difficult to maintain daily routines. It works well for individuals who experience pill fatigue and prefer to minimize healthcare visits while maintaining consistent HIV protection.
It is also especially helpful for those who face adherence challenges related to mental health concerns, substance use, or unstable housing, offering reliable prevention with fewer opportunities for missed doses.
Adverse Effects: What the Trials Documented
No medical intervention is without trade-offs.
Oral PrEP: Generally well-tolerated. Mild nausea or headache during initiation, typically resolving. Long-term concerns include renal function and bone mineral density, requiring periodic laboratory monitoring.
Cabotegravir injectable: Injection site reactions (pain, swelling) are common, typically grade 1–2. In HPTN 083, 6% of participants discontinued due to adverse events; in HPTN 084, 1% discontinued. Headache, fatigue, and pyrexia also reported.
Lenacapavir injectable: Injection site reactions most common, mild to moderate severity. No significant safety signals identified in PURPOSE trials. Weight ≥35 kg (77 lbs) required for administration.
The Adherence Argument: Why This Matters
Approximately 39,000 Americans received an HIV diagnosis in 2023. PrEP uptake, while improved, has not reached the populations with highest incidence: Black and Latino gay men, Black cisgender women, transgender women, and people who inject drugs.
Daily pills require daily motivation. Long-acting injectables shift the burden from the patient to the healthcare system. But that shift only works if the system delivers. Patients must be able to schedule appointments, transportation must be available, and insurers must cover the medication without imposing six-month oral PrEP trial requirements, a practice that violates federal rules but persists.
Coverage and Cost: What Patients Actually Pay
Oral PrEP: Generic. Low cost. Insurers must cover without cost-sharing under USPSTF Grade A recommendation.
Cabotegravir injectable: Higher acquisition cost. USPSTF review pending as of early 2026, though CDC guidelines recommend it and many insurers cover it. Federal Employee Health Benefits plans must cover all PrEP modalities for plan year 2026. Cost-sharing barriers continue to require patient advocacy and navigation assistance.
Lenacapavir injectable: Newly approved. CDC now strongly recommends it. However, some insurers, including CVS Health, have been publicly called out by the HIV+Hepatitis Policy Institute and 64 allied organizations for failing to cover lenacapavir despite federal requirements.
At Reza Health, PrEP navigation is a core service. For uninsured patients, we assist with manufacturer assistance programs and PrEP for uninsured coverage. You do not navigate insurance logistics alone.
How to Decide: A Framework
No algorithm determines the right PrEP modality. The decision requires conversation.
Consider daily oral PrEP if:
- You take other daily medications without difficulty
- You prefer managing your health outside clinical settings
- You have contraindications to intramuscular or subcutaneous injections
- You want the most extensively studied, longest-track-record option
Consider every-two-month injectable (cabotegravir) if:
- You want to discontinue daily pills
- You are comfortable with gluteal injections every 60 days
- You have reliable transportation to appointments every two months
- You prefer knowing exactly when you are protected without daily reminders
Consider twice-yearly injectable (lenacapavir) if:
- You travel extensively or have unpredictable schedules
- You have adherence barriers that cannot be resolved with daily pills
- You prefer the lowest possible visit frequency
- You are at least 35 kg and have no contraindications to subcutaneous injection
What Remains Constant Regardless of Modality
All PrEP requires baseline HIV testing. You must be HIV–negative at initiation. All PrEP requires periodic laboratory monitoring: HIV status confirmation, renal function, and STI screening. At Reza Health, these services are bundled into the prevention visit, with cost–sharing eliminated for insured patients and sliding–scale options available.
The Patient Perspective
Patients describe the injectable experience in specific terms. Privacy is cited frequently. No pill bottle visible to roommates, family members, or partners who do not know they take PrEP. No monthly pharmacy interactions. No daily confrontation with HIV risk.
Other patients describe the opposite preference. They want control in their own hands. They do not want to depend on appointment availability, injection appointments, or someone else’s schedule. They take their pill with morning coffee and do not think about HIV prevention again until the next day.
Neither orientation is incorrect.
The Reza Health Approach
Our team does not promote one modality over another. We present the best PrEP options with their respective efficacy data, adverse event profiles, adherence requirements, and real-world access barriers. We assess your risk factors, sexual health history, and lifestyle. We order the baseline laboratories. We prescribe the modality that aligns with your stated preferences.
If you start oral PrEP and later decide injections suit you better, we transition you. If you start injectable PrEP and find the appointments burdensome, we transition you back. These are not permanent decisions.
Frequently Asked Questions (FAQ)
Oral PrEP protects rectal tissue in 7 days, vaginal tissue in 21 days. Cabotegravir requires two injections one month apart before full protection. Lenacapavir reaches protective levels faster; your provider will advise exact timing.
Yes. First injection occurs while continuing oral PrEP. Stop oral medication only after injectable reaches protective concentration.
No. Appointment takes 10–15 minutes. No recovery time needed.
Contact Reza Health immediately. We determine if oral PrEP bridging is necessary based on how late you are.
Yes for patients ≥35 kg (77 lbs). Both cabotegravir and lenacapavir approved at this threshold.
Summary
The era of “one PrEP option” closed in 2021 and definitively ended in 2025. Patients now choose between daily pills, bimonthly injections, and twice-yearly injections. Each option, when used as directed, prevents HIV acquisition with high certainty. Each option fails when adherence fails.
The choice is not about which drug is stronger. The choice is about which adherence schedule you can sustain.
Reza Health provides all three modalities. We do not require six months of oral PrEP before considering injectables. We do not discourage oral PrEP in favor of newer products. We present the data, address your barriers, and support whichever decision you make.
Ready to Choose Your PrEP Modality for 2026?
If you are considering PrEP or have been on oral PrEP and wonder whether injectables might fit your life better, schedule a PrEP consultation at Reza Health.
📍 Jacksonville
📍 Jacksonville Beach
📍 Ormond Beach
📞 Call 888-831-2949 or book PrEP appointment online anytime.
Your prevention should match your actual life, not an idealized version of it. We will help you find the match.